Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Triastek to Start US Trials of Third 3D Printed Therapy

publication date: Nov 21, 2022

Nanjing Triastek was cleared to start US trials of T21, a 3D printed medicine for ulcerative colitis. The company uses the 3D dosage design to deliver the medication directly to the colon segment of the GI tract. Because approved UC drugs treat the condition systemically, Triastek believes T21, a novel drug, will allow lower dosing, causing fewer side effects. T21 is the company’s third 3D printed drug approved for clinical trials in the US. Previously, Triastek was approved to start trials of 3D drugs for rheumatoid arthritis and cardiovascular/clotting disorders. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital